Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 8, 2012, Pages 1306-1315

  Choi, Hye Joung ^a   Zhu, Bao Ting ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

2 Methoxyestradiol; Anti microtubule agents; Cyclin dependent kinases; MAD2; Mitotic prometaphase arrest

Indexed keywords

2 METHOXYESTRADIOL; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN MCF 7; CELL STRAIN MDA MB 435S; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MITOSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMETAPHASE; PROTEIN SYNTHESIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS SHAPE; CYCLIN B; CYCLIN B1; ESTRADIOL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; PROMETAPHASE; REPRESSOR PROTEINS; RNA INTERFERENCE; UP-REGULATION;

EID: 84862295461     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.05.003     Document Type: Article

References (41)

1. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19:1-27.
2. Zhu B.T., Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res. 1998, 58:2269-2277.
3. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994, 368:237-239.
4. Klauber N., Parang S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997, 57:81-86.
5. Pribluda V.S., Gubish E.R., Lavallee T.M., Treston A., Swartz G.M., Green S.J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000, 19:173-179.
6. Lin H.L., Liu T.Y., Wu C.W., Chi C.W. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001, 92:500-509.
7. Tinley T.L., Leal R.M., Randall-Hlubek D.A., Cessac J.W., Rao P.N., Mooberry S.L. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res. 2003, 63:1538-1549.
8. Liu Z.J., Zhu B.T. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2004, 88:265-275.
9. Han G.Z., Liu Z.J., Shimoi K., Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 2005, 65:387-393.
10. Davoodpour P., Landström M. M, 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J. Biol. Chem. 2005, 280:14773-14779.
11. Ray G., Dhar G., Van Veldhuizen P.J., Banerjee S., Saxena N.K., Sengupta K., Banerjee S.K. Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 2006, 45:3703-3713.
12. Stander B.A., Marais S., Vorster C.J., Joubert A.M. In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J. Steroid Biochem. Mol. Biol. 2010, 119:149-160.
13. Lin H.L., Liu T.Y., Chau G.Y., Lui W.Y., Chi C.W. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000, 89:983-994.
14. 2/M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 2001, 285:1259-1266.
15. 2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res. 2004, 24:873-880.
16. Fukui M., Zhu B.T. Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol. Carcinog. 2009, 48:66-78.
17. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., Fife K., Armstrong V., Treston A., Sidor C., Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 2005, 11:6625-6633.
18. Sweeney C., Porter J., Selbe K., Treston A., Quon C., Sidor C. A single-center, safety and pharmacokinetic study of 2-methoxyestradiol Nanocrystal® colloidal dispersion (Panzem®NCD), administered orally to patients with advanced cancer. Clin. Cancer Res. 2005, 11:B121.
19. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., McNally D., Parr A., Nguyen D., Yang S.X., Steinberg S.M., Venitz J., Sparreboom A., Figg W.D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther. 2006, 5:22-27.
20. Rajkumar S.V., Richardson P.G., Lacy M.Q., Dispenzieri A., Greipp P.R., Witzig T.E., Schlossman R., Sidor C.F., Anderson K.C., Gertz M.A. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res. 2007, 13:6162-6167.
21. Tevaarwerk A.J., Holen K.D., Alberti D.B., Sidor C., Arnott J., Quon C., Wilding G., Liu G. Phase I trial of 2-methoxyestradiol nanocrystal dispersion in advanced solid malignancies. Clin. Cancer Res. 2009, 15:1460-1465.
22. Harrison M.R., Hahn N.M., Pili R., Oh W.K., Hammers H., Sweeney C., Kim K., Perlman S., Arnott J., Sidor C., Wilding G., Liu G. A phase II study of 2-methoxyestradiol (2ME2) Nanocrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest. New Drugs 2010, 10.1007/s10637-010-9455-x.
23. 2/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinog. 2001, 31:111-124.
24. Ghosh R., Ott A.M., Seetharam D., Slaga T.J., Kumar A.P. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: therapeutic implications?. Melanoma Res. 2003, 13:119-127.
25. Perez-Stable C. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006, 231:49-64.
26. D'Amato R.J., Lin C.M., Flynn E., Folkman J., Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3964-3968.
27. Attalla H., Makela T.P., Adlercreutz H., Andersson L.C. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biophys. Res. Commun. 1996, 228:467-473.
28. Jordan M.A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 1998, 10:123-130.
29. Mollinedo F., Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8:413-450.
30. Wendell K.L., Wilson L., Jordan M.A. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochore-microtubule attachment and in centrosomes. J. Cell Sci. 1993, 104(Pt 2):261-274.
31. Vasquez R.J., Howell B., Yvon A.M., Wadsworth P., Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol. Biol. Cell 1997, 8:973-985.
32. Wang T.H., Popp D.M., Wang H.S., Saitoh M., Mural J.G., Henley D.C., Ichijo H., Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 1999, 274:8208-8216.
33. Morgan D.O. Principles of Cdk regulation. Nature 1995, 374:131-134.
34. Zoubine M.N., Weston A.P., Johnson D.C., Campbell D.R., Banerjee S.K. 2-Methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int. J. Oncol. 1999, 15:639-646.
35. Du B., Zhao Z., Sun H., Ma S., Jin J., Zhang Z. Effects of 2-methoxyestradiol on proliferation, apoptosis and gene expression of cyclin B1 and c-Myc in esophageal carcinoma EC9706 cells. Cell Biochem. Funct. 2012, 30:158-165.
36. Joubert A., Marais S. In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells. Cell Biochem. Funct. 2007, 25:357-362.
37. Agarwal N., Tochigi Y., Adhikari A.S., Cui S., Cui Y., Iwakuma T. MTBP plays a crucial role in mitotic progression and chromosome segregation. Cell Death Differ. 2011, 18:1208-1219.
38. Elledge S.J., Harper J.W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 1994, 6:847-852.
39. Xiong Y., Zhang H., Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 1993, 7:1572-1583.
40. Li Y., Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996, 274:246-248.
41. Maurer M., Komina O., Wesierska-Gadek J. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Ann. N. Y. Acad. Sci. 2009, 1171:250-256.